Key Highlights
- Tishtha, a biosimilar of nivolumab, launched by Zydus Lifesciences in India.
- Priced at ₹13,950 for 40 mg and ₹28,950 for 100 mg, significantly lower than the original.
- The drug is used for immunotherapy in various advanced cancers, including lung and head-and-neck cancers.
- Zydus received clearance from the Delhi High Court to launch the drug despite existing patent until May 2026.
- Over 500,000 patients are estimated to benefit from this new affordable treatment.
